| Literature DB >> 31413826 |
Laura Moles1, Marta Gómez1,2, Elena Moroder1, Esther Jiménez1, Diana Escuder3, Gerardo Bustos3,4, Ana Melgar3,4, Jeniffer Villa5, Rosa Del Campo6, Fernando Chaves5, Juan M Rodríguez1.
Abstract
Background: Nosocomial sepsis is the main problem that preterms have to face during their stay at neonatal intensive care units (NICU). Serratia marcescens is an emerging cause of preterm sepsis but its epidemiology is still largely unknown. Consequently, the aims of this study were to know the rate of preterms colonized by S. marcescens during their stay at the NICU and the characteristics and evolution of the S. marcescens population, including the susceptibility to clinically relevant antibiotics.Entities:
Keywords: Prematurity - antiobiotic resistance - gut colonization - sepsis - enteral feeding tubes
Mesh:
Substances:
Year: 2019 PMID: 31413826 PMCID: PMC6688303 DOI: 10.1186/s13756-019-0584-5
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Means (95% Confidence Interval) of the Demographic Data and Clinical Characteristics of Preterm Infants Participating this Study
| Characteristics | Mean (95% CI) or n (%) | ||
|---|---|---|---|
| Colonizated by | Not colonizated by | TOTAL | |
| Infant | 18 (69%) | 8 (31%) | 26 (100%) |
| Gestational age (wk) | 27.8 (26.6;28.9) | 27.4 (24.6;30.2) | 27.7 (26.6;28.7) |
| Gender | |||
| Male | 6 (33%) | 7 (87%) | 13 (50%) |
| Female | 12 (67%) | 1 (13%) | 13 (50%) |
| Birth weight (g) | 1100.56 (927;1274.1) | 1317.5 (804.5;1830.5) | 1167 (987.3;1347.3) |
| Delivery mode | |||
| Vaginal | 6 (33%) | 6 (75%) | 12 (46%) |
| Cesarean section | 12 (67%) | 2 (25%) | 14 (54%) |
| Antibiotherapy (days) | |||
| No | 1 (6%) | 1 (13%) | 2 (8%) |
| Yes | 17 (94%) | 7 (87%) | 24 (92%) |
| <3 days | 8 (44%) | 3 (37%) | 11 (42%) |
| >3 days | 9 (50%) | 4 (50%) | 13 (50%) |
| Bronchopulmonary dysplasia | |||
| No | 11 (61%) | 4 (50%) | 15 (58%) |
| Yes | 7 (39%) | 4 (50%) | 11 (42%) |
| Chorioamnionitis | |||
| No | 16 (89%) | 8 (100%) | 24 (92%) |
| Yes | 2 (11%) | 0 (0%) | 2 (8%) |
| Sepsis | 4 (22%) | 3 (38%) | 7 (27%) |
| Parenteral nutrition, | 7 (5-9.5)a | 11 (5.5-12.8)a | 7.5 (5-12.8)a |
| Enteral feeding tube (days) | 58 (45.7;69.9) | 61.5 (21.9;101.1) | 59 (46;72) |
| Mechanical ventilation, | 2 (0.8-9.5)a | 37 (35-37)a | 8.5 (1-35.5)a |
| CPAP, n=21 (days) | 11 (5.3-45.8)a | 5 (1.8-22)a | 9 (5-45)a |
| Oxygenotherapy, n=20 (days) | 27 (2.5-76.3)a | 41 (2-92)a | 32 (2-84)a |
| NICUs (days) | 43 (27.3-66)a | 30.5 (7.8-85.8)a | 42 (18.5-77.8)a |
| Hospital stay (days) | 68 (44.8-81.3)a | 39 (27-105.5)a | 64 (41-90)a |
a Median (IQR)
Serratia marcescens and other Enterobacteriaceae Isolated from Meconium and Fecal Samples from the first month of life of the infants
| Meconium ( | 1st week feces ( | 2nd week feces ( | 3rd week feces ( | 4th week feces ( | |||
|---|---|---|---|---|---|---|---|
|
| n (%) | 0 (0%) | 5 (28%) | 11 (48%) | 13 (54%) | 6 (55%) | <0,05** |
| Microbial Counts Median (IQR) | - | 8,462 (8,332-9,230) | 9,079 (8,942-9,593) | 9,333 (8,683-9,557) | 8,676 (7,874-9,195) | 0,114* | |
| Other | n (%) | 1 (6%) | 14 (78%) | 19 (83%) | 20 (83%) | 11 (100%) | <0,05** |
| Microbial Counts Median (IQR) | 7,267 (7,267-7,267) | 9,154 (8,484-9,515) | 9,322 (9,007-9,487) | 9,145 (9,038-9,517) | 9,362 (8,971-9,660) | 0,415* | |
**Fisher test
*KW test
Fig. 1Mean (IC 95%) concentration of S. marcescens (log10 CFU/g) in the different milk types after their pass through the feeding tubes. Donor milk: 5.06 (3.75; 6.36); formula: 3.20 (− 0.13; 6.53); own mother’s milk: 5.18 (4.51; 5.84)
Fig. 2Cluster analysis and antibiotic susceptibility of the different S. marcescens PFGE profiles obtained in this study. P1-P7: Profiles 1 to 7; P3*: Profile 3 obtained from the blood of the infants suffering bacteriemia. The cluster analysis was performed using the UPGMA method based on Dice similarity coefficient. Results of the antibiotic susceptibility assays are expressed by percentage of resistance using a color scale. AMC, amoxicilin/clavulanic acid; TZP, piperacillin/tazobactam; CXM, cefuroxime; CXM A, cefuroxime; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ETP, ertapenem; IPM, imipenem; AN, amikacin; GM, gentamicin; NA, nalidixic acid; CIP, ciprofloxacin; TGC, tigecycline; SXT, trimethoprim/sulfamethoxazole
Fig. 3(a) PFGE profiles of S. marcescens in feces and milk samples of the infants along the first four weeks of life. (b) Colonization rates of each PFGE profile of S. marcescens along the study period